Alexandra Teixeira

Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study

Zev A. Wainberg, Peter C. Enzinger, Yoon‐Koo Kang et al. · The Lancet Oncology · 2022 · 201 citations

Surgical Oncology, Esophageal Cancer, Gastrointestinal Oncology +11

Gla-Rich Protein Acts as a Calcification Inhibitor in the Human Cardiovascular System

Carla Viegas, Marta S. Rafael, J.L. Enriquez et al. · Arteriosclerosis Thrombosis and Vascular Biology · 2014 · 121 citations · Full text

Randomized double-blind placebo-controlled phase 2 study of bemarituzumab combined with modified FOLFOX6 (mFOLFOX6) in first-line (1L) treatment of advanced gastric/gastroesophageal junction adenocarcinoma (FIGHT).

Zev A. Wainberg, Peter C. Enzinger, Yoon‐Koo Kang et al. · Journal of Clinical Oncology · 2021 · 76 citations

Immunology, Gastroenterology, Pathology +17

Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial

Zev A. Wainberg, Yoon‐Koo Kang, Keun‐Wook Lee et al. · Gastric Cancer · 2024 · 57 citations · Full text

Profiling DNA mutation patterns by SERS fingerprinting for supervised cancer classification

Lei Wu, Alexandra Teixeira, Alejandro Garrido‐Maestu et al. · Biosensors and Bioelectronics · 2020 · 50 citations

Functional Genomics, Engineering, Somatic Variant +14